Published: March 2017 | Report Code: LS10796 | Available Format: PDF | Pages: 173
Note: This report can also be updated as of date and delivered within 1-2 working days of purchase confirmation
Estrogen Receptor-Positive (ER+) breast cancer is the most common type of breast cancer diagnosed and it refers to the cancer cells that have receptors on their surface to bind with estrogen. Breast cancer is said to be estrogen receptor-positive (ER+), if it contains estrogen that receives signals from estrogen to promote cell growth. Breast cancer is a syndrome that affects breast tissues and cells in the breast grow in an uncontrollable manner forming a tumor, which can be felt as a lump or can be viewed under x-ray. Majority of breast cancers begin in lobules, tissues which are made up of glands for milk production and ducts that connect the lobules to the nipple. The risk factor of the disease includes personal or family medical history or certain changes in their genes. The increased life expectancy, shift toward urbanization and adoption of western lifestyles are the common factors instigating the risk of development of breast cancer. Early detection of ER+ breast cancer is important for the improvement of breast cancer outcome and survival.
Breast cancer still remains the major cause of deaths among women, but in coming years, it is likely that mortality and morbidity would increase in much less proportion than the standard reckoning, and there is even a possibility of decrease in the rate of occurrence of the disease. There are several reasons that are likely to contribute to the same, such as progress in screening/diagnosis, which leads to early detection of the tumor, making it more acquiescent for treatment.
The second reason can be progress in the pharmacological treatment and incursion of new drugs such as tamoxifen, which have been highly effective in the treatment of contralateral breast cancer in ER+ patients.
Thirdly, the pipeline is very profuse; new therapeutic agents are under development, which are likely to become available in next few years.
As of February 2017, the ER+ breast cancer pipeline comprised of approximately 74 drug candidates in different stages of development.
NUMBER OF ER+ BREAST CANCER DRUG CANDIDATES UNDER DEVELOPMENT (2017)
Some of the key players developing drugs for ER+ breast cancer includes Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc. and others.
P&S Intelligence offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws